Research for Major Depressive Disorder

In the United States it is reported that upwards of 70% of patients with Major Depressive Disorder (MDD) are partial or non-respondents to the first- line therapies which include SSRIs and SNRIs.

Designation FOR Adjunctive Treatment of Major Depressive Disorder (MDD), has a mechanism of action which is entire different from that of atypical anti-psychotics. The drug, rapastinel, is an N-methyl-D-aspartate receptor (NMDAR) modulator with a novel and complete pharmacological mechanism of action, acting as a non-selective agent at NR2 subunits and displaying properties as a functional partial agonist in a number of pharmacological assays.

At APG Clinical Research, we are conducing more research into this new drug, and invite you to refer people who meet the following criteria:
- Ages 18 and up
- With a current major depressive episode in the last 8 weeks and not exceeding 18 months in duration
- And, have no more than partial response (<50% improvement) to ongoing treatment with a protocol- allowed antidepressant

APG Research provides extensive service to our sponsors, physicians and research patients. Our team has a combined 40 years of clinical research experience in adult and pediatric studies including Major Depression, Autism, Anxiety, Bipolar, OCD, ADHD and Schizophrenic Disorders.

Call today to see if your child would benefit from participating in one our studies.

apgresearch.net | 407-423-7149 | plus.google.com/+APGresearchNet